New Study Results from Uganda Strengthen the Case for Contraceptive Self-Injection

April 13, 2018

(Medical Xpress) – Evidence published today on a new contraceptive option is providing one possible answer to an age-old question in family planning: how to address barriers that make it difficult for women to keep using contraception consistently. Results from a PATH study in Uganda, now published in the journal Contraception, show that self-injection of subcutaneous DMPA (DMPA-SC, marketed as Pfizer’s Sayana Press) may help to continue using injectable contraception longer than women who receive traditional intramuscular injections (DMPA-IM) from providers.

Recommended Reading